Document Detail


Aspirin and reproductive outcomes.
MedLine Citation:
PMID:  18081940     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the late 1980s and early 1990s, researchers hypothesized that aspirin could be used to prevent or delay the onset of preeclampsia. This hypothesis was tested in numerous trials which showed limited, but positive results. Subsequently, aspirin has been used in an attempt to improve pregnancy outcomes in women who have both antiphospholipid antibodies and a history of recurrent loss, and has also been used in an attempt to improve the success of in vitro fertilization. In theory, aspirin has both positive and negative effects on reproduction. Aspirin, which suppresses cyclooxygenase, has the potential to interfere with implantation, but also has the potential to support the maintenance of pregnancy. Aspirin is prescribed with increasing frequency to reduce the risk of maternal thrombosis and reduce the risk of miscarriage and poor pregnancy outcome. Aspirin alone, however, is not considered sufficient to prevent thrombosis and even in women with the antiphospholipid syndrome, the question as to whether low-dose aspirin improves pregnancy outcomes has not been answered affirmatively. Aspirin has potential risks. Aspirin inhibits platelet function and can contribute to maternal and fetal bleeding. Aspirin crosses the placenta. Although aspirin has not been associated with other congenital anomalies, it has been associated with an increased risk of vascular disruptions, particularly gastroschisis and possibly premature closure of the ductus arteriosus. Nonetheless, large trials demonstrate low-dose aspirin's relative safety and generally positive effects on reproductive outcomes.
Authors:
Andra H James; Leo R Brancazio; Thomas Price
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Obstetrical & gynecological survey     Volume:  63     ISSN:  0029-7828     ISO Abbreviation:  Obstet Gynecol Surv     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-17     Completed Date:  2008-02-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401007     Medline TA:  Obstet Gynecol Surv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  49-57     Citation Subset:  IM    
Affiliation:
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA. andra.james@duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced
Antibodies, Antiphospholipid / drug effects
Aspirin / administration & dosage*,  adverse effects,  pharmacokinetics
Cyclooxygenase Inhibitors / administration & dosage*,  adverse effects,  pharmacokinetics
Dose-Response Relationship, Drug
Female
Fertilization in Vitro / drug effects
Hemorrhage / chemically induced
Humans
Pre-Eclampsia / drug therapy
Pregnancy
Pregnancy Complications / drug therapy*
Pregnancy Outcome
Thrombosis / prevention & control
Chemical
Reg. No./Substance:
0/Antibodies, Antiphospholipid; 0/Cyclooxygenase Inhibitors; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polycystic ovary syndrome and oocyte developmental competence.
Next Document:  Cervical cerclage: a review of the evidence.